According to a post on the FDA’s website, Corvus Pharmaceuticals’ treatment of T-cell lymphoma received orphan designation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRVS:
- Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
- Corvus announced new interim data from Phase 1/1b trial of soquelitinib
- Corvus Pharmaceuticals
- Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
